Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High – Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price reached a new 52-week high on Monday . The company traded as high as $43.75 and last traded at $43.6290, with a volume of 243489 shares changing hands. The stock had previously closed at $41.45.

Analysts Set New Price Targets

A number of equities analysts have commented on DNTH shares. Wedbush upped their price objective on shares of Dianthus Therapeutics from $44.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Guggenheim boosted their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. HC Wainwright increased their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Robert W. Baird raised their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, September 9th. Finally, Raymond James Financial reissued an “outperform” rating and set a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $63.43.

Dianthus Therapeutics Stock Down 0.1%

The company has a market cap of $1.89 billion, a PE ratio of -12.65 and a beta of 1.56. The firm’s fifty day simple moving average is $36.70 and its 200-day simple moving average is $26.71.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. On average, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Simrat Randhawa sold 109,031 shares of the company’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $152,560. This represents a 96.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 216,538 shares of company stock valued at $8,079,575. Company insiders own 16.56% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at $27,000. US Bancorp DE raised its position in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after buying an additional 1,510 shares during the period. Parkside Financial Bank & Trust boosted its holdings in Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 540 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics during the third quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC increased its stake in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.